Bayer’s Stock Holds the Line at a Key Technical Level as Finerenon Data Bolsters the Pipeline

Bayer shares hover near critical 200-day moving average support after positive Finerenon kidney drug results from FIND-CKD and INFINITY trials. Analysts see 36% upside, but litigation and macro risks remain.

Bayer’s shares ended last week at €35.95, a mere 15 cents above the 200-day moving average of €35.80 — a line in the sand that now defines the immediate trend. Below that level, the chart offers no further support. Above it, the stock faces a long climb back to the 50?day average of €38.39 and the 100?day line at €40.50, which lie 6.4% and 12% higher, respectively. The relative strength index of 42.6 suggests the equity is weak but not yet in panic territory, having shed 1.45% over the past week and 5.46% since the start of 2026.

Against this fragile technical backdrop, Bayer served up two clinical datasets for its kidney drug Finerenon (marketed as Kerendia) that could, over time, reshape the investment case. The pivotal FIND?CKD trial met its primary endpoint in adults with non?diabetic chronic kidney disease, slowing the decline in kidney function by a statistically significant 0.7?ml/min/1.73?m² per year versus placebo. A composite cardiovascular?renal secondary endpoint was cut by 23%. The results were simultaneously presented at the ERA congress and published in the New England Journal of Medicine. Bayer intends to file for regulatory approval in this new indication, though no timeline has been given.

A companion analysis, INFINITY, pooled data from all three completed phase?3 studies — FIDELIO?DKD, FIGARO?DKD and FIND?CKD — covering roughly 14,500 patients. It showed that Finerenon reduced the primary composite renal endpoint by 24% and cut the risk of hospitalisation for heart failure or cardiovascular death by 20%. Those figures appeared in The Lancet on the same day, giving regulators an unusually robust evidence base. Finerenon is one of the few growth drivers in Bayer’s pharma unit, which posted first?quarter sales of €4.249?billion — flat year?on?year, as gains from Kerendia and Nubeqa offset patent losses elsewhere.

The immediate question for the stock is whether the fresh data can act as a catalyst strong enough to pull the share price away from the 200?day support. On a 30?day view, the equity has dropped nearly 7%, and the 52?week high of €49.93 from February 2026 remains 28% above current levels. The 52?week low of €25.09, by contrast, sits 43% below. Analysts are broadly positive: nine of the eleven covering the stock rate it a buy, with a consensus price target of €48.82 that implies substantial upside. Whether that optimism becomes action depends on the market’s reading of the Finerenon data as a durable fundamental shift.

External events will test the direction this week. Bayer’s next corporate update is the half?year report on August 4, and the Monsanto litigation overhang remains — recent Reuters reporting indicated the company is not pursuing a spin?off, instead focusing on operational improvements and legal management. Meanwhile, the European Central Bank meets on June 10–11 to set monetary policy, and the US Department of Labor releases May inflation figures on June 10. For a stock balanced on a single technical edge, such macroeconomic signals can amplify whatever move the market chooses to make.